Dynavax Technologies Corporation (DVAX.W)
1.49USD
5 Feb 2010
$0.05 (+3.47%)
$1.49
--
$1.60
$1.45
230,232
589,451
$3.35
$0.50
DVAX.W
About
Overall
| Beta: | 3.10 |
| Market Cap (Mil.): | $61.51 |
| Shares Outstanding (Mil.): | 41.28 |
| Annual Dividend: | 0.00 |
| Yield (%): | NA |
Financials
| DVAX.W | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 20.84 | 11.50 | 3.76 |
| EPS (TTM): | 107.90 | -- | -- |
| ROI: | -2.31 | 1.25 | 2.30 |
| ROE: | 20.11 | 2.09 | 2.82 |
UPDATE 2-Dynavax hepatitis C drug shows promise in phase 1 trial
* All patients at highest dose saw reduction in viral load
BEFORE THE BELL-Dynavax Tech shares surge after comments on drug
NEW YORK, Jan 26 (Reuters) - Shares of Dynavax Technologies Corp surged 32 percent to $1.97 in premarket trading on Tuesday after the company said its experimental treatment for chronic hepatitis C infection was safe and induced anti-viral activity in patients in an early-stage trial.
UPDATE 4-Dynavax shares soar as hepatitis B trials resume
* Shares jump 45.7 percent (Updates with analyst comment, closing share price)
BEFORE THE BELL-Dynavax shares up after FDA move
NEW YORK, Sept 10 (Reuters) - Shares of Dynavax Technologies rose 71 percent to $3 in premarket trading on Thursday, after regulators gave it the green light to move forward with its experimental hepatitis B vaccine.
FDA gives Dynavax OK to resume hepatitis B trials
BOSTON (Reuters) - Dynavax Technologies Corp said on Thursday that U.S. regulators have given it the green light to move forward with its experimental hepatitis B vaccine.
US RESEARCH SUMMARY-Non-S&P 500 March 20 2048 GMT
Following is a summary of research actions on non-S&P 500 companies reported
UPDATE 1-FDA asks for more data on Dynavax's hepatitis vaccine
Feb 9 (Reuters) - Dynavax Technologies Corp said U.S. health regulators asked for additional information on its experimental hepatitis B vaccine, Heplisav, and maintained a clinical hold on the drug.
UPDATE 1-Dynavax ends deal with Merck for Hepatitis B vaccine
Dec 19 (Reuters) - Drug developer Dynavax Technologies Corp said it ended a global license and development deal with Merck & Co Inc for its experimental hepatitis B vaccine, Heplisav.
Glaxo, Dynavax forge drug research deal
NEW YORK (Reuters) - GlaxoSmithKline Plc said on Wednesday it will pay Dynavax Technologies Corp $10 million upfront and potential future large milestone payments in a research deal involving drugs to treat autoimmune and inflammatory diseases.
Glaxo, Dynavax forge drug research deal
NEW YORK (Reuters) - GlaxoSmithKline Plc said on Wednesday it will pay Dynavax Technologies Corp $10 million upfront and potential future large milestone payments in a research deal involving drugs to treat autoimmune and inflammatory diseases.
Competitors
| Price | Change | |
|---|---|---|
| GlaxoSmithKline plc (GSK.L) | £1,206.00 | -12.50 |
| Crucell N.V. (CRCL.AS) | €14.07 | +0.04 |
| ALK-Abello A/S (ALKb.CO) | kr.420.00 | +9.50 |
| Schering-Plough Corporation (SGP.N) | -- | -- |
| Allergy Therapeutics plc (AGY.L) | £13.75 | 0.00 |
| Cytos Biotechnology AG (CYTN.S) | CHF12.50 | +0.25 |
| Merck & Co., Inc. (MRK.N) | $36.47 | -0.12 |
| AstraZeneca plc (AZN.L) | £2,826.50 | +11.00 |
| Novartis AG (NOVN.VX) | CHF57.20 | +0.40 |
| Sanofi-Aventis SA (SASY.PA) | €53.14 | +0.48 |
Earnings vs 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
